Author(s): Ardalan Mohammad Reza
Journal: Journal of Renal Injury Prevention
ISSN 2345-2781
Volume: 2;
Issue: 2;
Start page: 71;
Date: 2013;
VIEW PDF
DOWNLOAD PDF
Original page
Keywords: Membranous nephropathy | Nephrotic syndrome | Phospholipase A2 receptor | Anti-PLA2R antibody
ABSTRACT
Implication for health policy/practice/research/medical education:Phospholipase A2 receptor, is normally expressed in podocyte membrane. In fact the phospholipase A2 receptor (PLA2R) is a type I transmembrane glycoprotein related to the C-type animal lectin family such as the mannose receptor. PLA2R regulates a number of biological responses produced by secretory phospholipase A2s (sPLA2s). Determining anti-PLA2r serum levels in patients with nephrotic syndrome should designate a probable diagnosis of idiopathic membranous nephropathy and in patients in which idiopathic membranous nephropathy had a pathology confirmation may be a determining factor to exclude secondary forms of the disease. However, it is too early to abandon a kidney biopsy in patients with nephritic syndrome, and PLA2R as the newly introduced serologic study needs confirmations to finds its proper place in the field of clinical medicine.
Journal: Journal of Renal Injury Prevention
ISSN 2345-2781
Volume: 2;
Issue: 2;
Start page: 71;
Date: 2013;
VIEW PDF


Keywords: Membranous nephropathy | Nephrotic syndrome | Phospholipase A2 receptor | Anti-PLA2R antibody
ABSTRACT
Implication for health policy/practice/research/medical education:Phospholipase A2 receptor, is normally expressed in podocyte membrane. In fact the phospholipase A2 receptor (PLA2R) is a type I transmembrane glycoprotein related to the C-type animal lectin family such as the mannose receptor. PLA2R regulates a number of biological responses produced by secretory phospholipase A2s (sPLA2s). Determining anti-PLA2r serum levels in patients with nephrotic syndrome should designate a probable diagnosis of idiopathic membranous nephropathy and in patients in which idiopathic membranous nephropathy had a pathology confirmation may be a determining factor to exclude secondary forms of the disease. However, it is too early to abandon a kidney biopsy in patients with nephritic syndrome, and PLA2R as the newly introduced serologic study needs confirmations to finds its proper place in the field of clinical medicine.